Latest
Moving fast. Saying something real every time.
We publish when we have results worth reporting. In 2026, that has been roughly every two weeks. Here is where HARMONY stands today.
Validation · 2026
36/36 blind predictions correct across 5 independent peer-reviewed datasets. Every call time-stamped and cryptographically locked before the literature was checked.
2026
Pipeline · Jul 2026
Single HARMONY scaffold shows confirmed activity across four consecutive MAPK cancer pathway targets. No approved drug currently covers this combination.
July 2026
IP · Jul 2026
7 USPTO provisional patents confirmed. Priority chain from August 2025 through July 2026. PARP1, RET, BCR-ABL1, and ABCA4 filings complete.
July 2026
Wet Lab · Jun 2026
ABCC8/SUR1 wet lab validation signed and executing at Scientist.com. First prospective results targeting Q4 2026.
June 2026
Discovery · 2026
HARMONY independently re-derived tolbutamide — the first FDA-approved sulfonylurea, approved in 1957 — from protein backbone physics alone. Zero prior knowledge of its pharmacology.
2026
Company · 2026
InfiniGraph opens select investor inquiries. We are moving fast and we are selective about who moves with us.
2026
"
We don't announce things until they're real. Everything on this page is real.
Chase K. McMichael · Founder & CEO · July 2026